LIQ861 FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 30, 2020.
FDA Approved: No
Brand name: LIQ861
Generic name: treprostinil
Dosage form: Inhalation Powder
Company: Liquidia Technologies, Inc.
Treatment for: Pulmonary Arterial Hypertension (PAH)
LIQ861 (treprostinil) is an investigational inhaled dry powder formulation of treprostinil in development for the treatment of pulmonary arterial hypertension (PAH).
Development Timeline for LIQ861
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.